LIPO (Lipella Pharmaceuticals) EBITDA Margin %: 0.00% (As of Sep. 2025)

What is Lipella Pharmaceuticals EBITDA Margin %?

Lipella Pharmaceuticals LIPO +8.43% EBITDA Margin % is 0.00% as of Sep. 2025. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Lipella Pharmaceuticals ranks worse than 79.24% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lipella Pharmaceuticals's EBITDA for the three months ended in Sep. 2025 was $-1.27 Mil. Lipella Pharmaceuticals's Revenue for the three months ended in Sep. 2025 was $0.00 Mil. Therefore, Lipella Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2025 was 0.00%.

Lipella Pharmaceuticals (OTCPK:LIPO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lipella Pharmaceuticals EBITDA Margin % Related Terms

Lipella Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals EBITDA Margin % Chart

Lipella Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EBITDA Margin %

-5.61

-717.76

-1,406.52

-1,023.56

-935.26

Lipella Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25
EBITDA Margin %	Get a 7-Day Free Trial															0.00	-258.58	0.00	0.00	0.00

LIPO vs WINT, RMTG, CYTOF: EBITDA Margin % Comparison

For the Biotechnology subindustry, Lipella Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipella Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's EBITDA Margin % falls into.

Save Embed

Lipella Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lipella Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-5.013	/	0.536
	=	-935.26 %

Lipella Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2025 )	/	Revenue (Q: Sep. 2025 )
	=	-1.274	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Lipella Pharmaceuticals (LIPO) has a EBITDA Margin % of 0.00% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #748 out of 944 companies in the Biotechnology industry, placing it in the top 79.2%.

Is Lipella Pharmaceuticals' EBITDA Margin % too high?

Lipella Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Lipella Pharmaceuticals ranks #748 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.

How does Lipella Pharmaceuticals' EBITDA Margin % compare to WINT and RMTG?

According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #748 out of 944 companies for EBITDA Margin %. This places Lipella Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lipella Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.67, compared to a current price of $0.09 — trading 99% below its estimated fair value. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies WINT RMTG CYTOF IOBTQ CNBX EMMA ENDV RGBP CERO ADTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208

Website https://www.lipella.com

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.